Hartsell And Associates National Legal Nurse Consulting Services

National Alliance of Certified Legal Nurse Consultants
Nurse Alliance of Tennessee
American Nurses Association

Assisting Attorneys To Victory By Providing Over 33 Years Healthcare Expertise

V.I.P. Member of the Manchester Who's Who Among Executive and Professional Women
V.I.P Member of the Cambridge Who's Who of America

 

Newsletter

February 2008

Volume 2, No 2

                    Use The Person That Physicians Rely On - A RN -    

 
Botox, Botox Cosmetic (Botulinum toxin Type A),  and
Myobloc (Botulinum toxin Type B)

Posted 02/07/2008
" FDA issued an early communication about an ongoing safety review regarding Botox and Botox Cosmetic. FDA has received reports of systemic adverse reactions including respiratory compromise and death following the use of botulinum toxins types A and B for both FDA-approved and unapproved uses. The reactions reported are suggestive of botulism, which occurs when botulinum toxin spreads in the body beyond the site where it was injected. The most serious cases had outcomes that included hospitalization and death, and occurred mostly in children treated for cerebral palsy-associated limb spasticity. Use of botulinum toxins for treatment of limb spasticity (severe arm and leg muscle spasms) in children or adults is not an approved use in the U.S. See the FDA's "Early Communication about an Ongoing Safety Review" for Agency recommendations and additional information for healthcare professionals."

Source: The U.S. Food and Drug Administration

E. Coli - Does Tainted Food Smell Bad?

 

You can't tell whether a food is contaminated with E. coli by the way it looks, smells or tastes. Most types of the bacteria Escherichia coli (E. coli) are harmless. But a few nasty strains, such as E. coli O157:H7, can cause serious food-borne illness. To protect yourself from E. coli and other food-borne illnesses, follow basic food safety guidelines. Rinse raw produce thoroughly. Wash your hands, utensils and kitchen surfaces with hot, soapy water before and after preparing or eating food. Keep raw foods separate from ready-to-eat foods. Cook your food thoroughly, especially ground beef. Refrigerate or freeze perishable foods promptly. Avoid unpasteurized juices, ciders and dairy products. Don't drink untreated water from lakes or streams.

Source:  The Mayo Clinic

For More on E Coli:  Click Here
http://www.mayoclinic.com
/health/e-coli/DS01007

Nationwide Recall of  Icy Hot Heat Therapy Products Due to 1st, 2nd, and 3rd Degree Burns

Chattem, Inc. and FDA informed consumers and healthcare professionals of a voluntary nationwide recall of its Icy Hot Heat Therapy products, including consumer "samples" that were included on a limited promotional basis in cartons of its 3 oz Aspercreme product. The products were recalled because of consumer reports of first, second and third degree burns as well as skin irritation. All lots and sizes of the following Icy Hot Heat Therapy products were recalled:

1.  Icy Hot Heat Therapy Air
     Activated Heat - Back
2.  Icy Hot Heat Therapy Air
     Activated Heat - Arm, Neck,
     and Leg
3.  Icy Hot Heat Therapy Air
     Activated Heal - Arm, Neck,
     and Leg single consumer use
     "samples" on a limited
      promotional basis in cartons
      of 3 oz. Aspercreme Pain
      Relieving Cream

Source:  U.S. Food and Drug Administration

 

 

      

Oral Contraceptives Reduce Long-Term Risk of Ovarian Cancer


"Since they were first licensed nearly 50 years ago, birth control pills containing estrogen have prevented some 200,000 cases of ovarian cancer world-wide, estimate the authors of a study published January 26 in The Lancet. Further, in the absence of having taken oral contraceptives, half of these women would have died of the disease."

"The researchers showed that oral contraceptives (OCs) continue to confer protection for years - even decades - after women stop using them. Thus, they surmise, "the number of ovarian cancers prevented [will] rise over the next few decades" to at least 30,000 each year."

"These figures emerge from a comprehensive meta-analysis based on prospective and case-control data from 45 epidemiological studies in 21 countries, mostly in Europe and the United States. "These findings set a new standard in prevention for a deadly cancer," wrote the editors of The
Lancet
, "and have important public health implications."

"The results showed that women who had ever taken OCs were 27 percent less likely to develop ovarian cancer. The studies included 23,257 women with ovarian cancer, 31 percent of whom
had taken OCs; of the 87,303 controls, 37 percent took OCs."

"Another feature of these results is their uniformity. OCs seem to protect against nearly all types of epithelial and nonepithelial tumors, with the possible exception of mucinous ovarian cancer (which accounted for only 12 percent of cases studied in the meta-analysis). The Lancet editorial points out that the results show "the benefits of oral contraceptives are independent of the preparation [estrogen dose], and vary little by ethnic origin, parity, family history of breast cancer, body-mass index, and use of hormone replacement therapy."

"Dr. Beral commented that while OCs may pose a slight increased risk of breast and cervical cancer, the effect is small and disappears once the drugs are no longer being used, as contrasted with the ongoing protective effect against ovarian cancer."

"Dr. Karlan added, "Ovarian cancer remains a disease with a high mortality due [mainly] to our inability to reliably diagnose it at an early stage. Women are concerned about this risk." She noted that it is important for women to be aware that OCs reduce that risk when discussing their contraceptive choices with their health care providers."

Source:  The National Cancer Institute

http://www.cancer.gov/ncicancer
bulletin/NCI_Cancer_Bulletin_
020508/page2


 

High Caffeine Intake During Pregnancy May Increase Risk for Miscarriage 

"January 24, 2008 — A high intake of caffeine during pregnancy increased the risk for miscarriage, according to the results of a population-based, prospective cohort study reported in the January 21 Online First issue of the American Journal of Obstetrics & Gynecology."

"Caffeine can readily cross the placental barrier to the fetus; its clearance is prolonged in pregnant women, and its metabolism rate is low in the fetus because of low levels of enzymes," write Xiaoping Weng, PhD, from Kaiser Permanente in Oakland, California, and colleagues. "Although numerous studies on maternal caffeine consumption and the risk of miscarriage have been published since the 1980s, the effect of caffeine intake on the risk of miscarriage remains controversial because of methodological limitations. . . . The objective of this population-based prospective study was to examine the effect of maternal caffeine intake during pregnancy on the risk of miscarriage, taking into account a number of potential confounders, especially the impact of nausea or vomiting during pregnancy."

"This observed association was not significantly affected by nausea or vomiting during pregnancy or by the change in intake pattern of caffeine during pregnancy."

"Our results demonstrated that high doses of caffeine intake during pregnancy increase the risk of miscarriage, independent of pregnancy-related symptoms," the study authors write. "We provided new evidence that the observed association was not likely the result of confounding by the pregnancy-related symptoms of nausea, vomiting, and aversion to caffeine consumption. Therefore, it may be prudent to stop or reduce caffeine intake during pregnancy."

Summary:

"Caffeine has been extensively studied as a possible deleterious substance during pregnancy. It readily crosses the placental barrier, and clearance of caffeine is slower in pregnant vs nonpregnant women. The fetus has low levels of enzymes which break down caffeine, so fetal metabolism of caffeine is delayed."

"Some research has suggested that caffeine can reduce intervillous blood flow, but data regarding the role of caffeine in promoting miscarriage are limited because of questions regarding the methodology of this research. The current study recruited women early in pregnancy and adjusted for possible confounders in an attempt to address these methodologic flaws."

Laurie Barclay M.D.
Charles Vega M.D.

Source:  Medscape Medical News